There is no testosterone product approved by the FDA for women in the United States. Not one. Yet testosterone is prescribed to women every day, and the largest analysis of the randomized trials found it does work for one specific problem. Here is what the evidence supports, what it does not, and why the gap between the two is so wide.
Key facts
- As of 2026 there is no FDA-approved testosterone product for women in the U.S. Every prescription is off-label or compounded.
- The one use supported by international consensus is hypoactive sexual desire disorder (HSDD) in postmenopausal women.12
- A meta-analysis of 36 randomized trials found testosterone significantly improved sexual function in postmenopausal women, with no serious short-term safety signal.3
- Evidence does not support prescribing testosterone to women for fatigue, mood, bone density, cognition, or general wellbeing.1
- Long-term safety beyond about two years has not been established.13
Why there is no approved product
Testosterone is often described as a male hormone, which is misleading. It is present and biologically active in women throughout life, at roughly a tenth to a twentieth of male concentrations, and it declines gradually with age rather than dropping sharply at menopause.
Despite that, no manufacturer currently holds FDA approval for a female testosterone product in the United States. A patch designed for women, Intrinsa, was reviewed by an FDA advisory committee in 2004 and was not approved, largely over long-term safety data that did not exist. It was later approved in Europe and subsequently withdrawn for commercial reasons. Australia is one of the few countries with an approved female product.
The practical result is that American women who are prescribed testosterone receive either a fraction of a male-dose product, applied off-label, or a preparation made by a compounding pharmacy. Neither route is FDA-reviewed for this use, and compounded products are not subject to the same batch consistency requirements as approved drugs.
What the evidence actually supports
Sexual desire in postmenopausal women
This is the one indication where the evidence converges. A 2019 systematic review and meta-analysis pooled data from 36 randomized controlled trials covering more than 8,000 women, and found that testosterone significantly improved sexual desire, arousal, orgasm frequency, pleasure, and self-image, while reducing sexual distress, in postmenopausal women.3
That analysis directly informed the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, produced jointly by the International Menopause Society, the Endocrine Society, the American College of Obstetricians and Gynecologists, and several other bodies.1 Its conclusion is narrow and worth quoting in spirit: the only evidence-based indication for testosterone in women is hypoactive sexual desire disorder in postmenopausal women, after other contributing causes have been addressed.
The International Society for the Study of Women’s Sexual Health published a clinical practice guideline in 2021 reaching a compatible conclusion.2
Two things are worth being precise about. First, the effect is real but moderate, not transformative. Second, HSDD is a specific diagnosis involving persistent low desire that causes personal distress, not simply lower desire than one once had.
What the evidence does not support
The same consensus statement is explicit that available data do not support using testosterone in women for cognitive performance, bone density, cardiovascular health, mood, energy, general wellbeing, or musculoskeletal outcomes.1
This matters because those are precisely the reasons testosterone is most often marketed to women. The claim that testosterone will restore energy, sharpen thinking, protect bone, or improve body composition in women is currently ahead of the evidence. It may turn out to be true. It has not been shown.
Safety, and the limits of what is known
In the pooled trial data, testosterone given at physiological female doses did not produce serious adverse events over the study periods. Reported effects included acne and increased body or facial hair, generally mild. Non-oral routes, meaning patches, gels, and creams, did not adversely affect lipid profiles, whereas oral testosterone was associated with unfavorable lipid changes, which is one reason oral formulations are not recommended.3
The critical limitation is duration. Most trials ran six months to a year, some to two years. There is no long-term randomized safety data on breast cancer risk, cardiovascular events, or endometrial outcomes in women taking testosterone for a decade or more.1 Anyone who tells you long-term safety is established is overstating what has been studied.
Dose matters, and supraphysiological dosing is a real risk
The consensus is that doses should approximate premenopausal physiological concentrations. Because no female-dose product is approved in the U.S., dosing errors are a genuine hazard: applying a male-dose gel or receiving a compounded pellet calibrated too high can push levels well above the female range, producing voice deepening, clitoral enlargement, and male-pattern hair growth, some of which may not reverse.
This is one of the strongest practical arguments for having testosterone levels measured before and during treatment rather than dosing by symptoms alone.
Who should not take it
Testosterone is not appropriate during pregnancy or breastfeeding, because of the risk of virilizing a female fetus. It requires careful individual assessment in women with a history of hormone-sensitive cancer, significant liver disease, or untreated cardiovascular disease. These are decisions for a clinician who knows your full history.
The testing problem
There is a technical complication that rarely gets mentioned. Most routine testosterone assays were designed and validated for male concentrations, and they perform poorly at the much lower levels found in women. Liquid chromatography-mass spectrometry is the accurate method, and it is not what most standard panels use.4
A further wrinkle: there is no established blood level that defines testosterone deficiency in women. The consensus statement states plainly that no cut-off value can be used to diagnose it.1 Testing is used to avoid overdosing during treatment, not to establish a diagnosis beforehand. A clinic that tells you a lab number proves you are deficient is going beyond the evidence.
Questions worth asking a prescriber
- What specifically are we treating, and is it HSDD as a diagnosis?
- What other causes of low desire have we ruled out first, including relationship factors, depression, medications such as SSRIs, sleep, pain with intercourse, and thyroid function?
- What product and route, and how is a female-appropriate dose achieved?
- How will levels be monitored, and with which assay?
- What is the plan if it does not work after three to six months?
Frequently asked questions
Is testosterone therapy for women legal in the U.S.?
Yes. Prescribing an approved drug off-label is legal and common medical practice. What does not exist is an FDA-approved product specifically for women, which means dosing and formulation fall to the prescriber and, often, a compounding pharmacy.
Will testosterone help my fatigue or brain fog?
The current evidence does not support prescribing testosterone to women for fatigue, mood, or cognition. Those symptoms are common in midlife and frequently have other causes worth investigating first, including thyroid dysfunction, iron deficiency, sleep disruption, and depression.
Are pellets better than creams?
The trial evidence supporting testosterone in women is largely from patches, gels, and creams. Pellets deliver a fixed dose that cannot be adjusted or removed once implanted, and have been associated with supraphysiological levels. Non-oral, adjustable routes are what the guidelines describe.
Do I need testosterone if my level is “low” on a lab test?
No established blood level defines testosterone deficiency in women, and international consensus explicitly states that no cut-off should be used to diagnose it. A low number on a panel is not, by itself, a reason to treat.
The bottom line
Testosterone therapy for postmenopausal women with HSDD is supported by good evidence: multiple randomized trials, a large meta-analysis, and international consensus agree it improves sexual function with an acceptable short-term safety profile. That is a genuine finding and women who need it have often been dismissed.
Everything beyond that indication is currently unproven, long-term safety is unknown, no approved female product exists in the U.S., and no lab value defines deficiency. Both halves of that picture are true at once, and most of what you will read online gives you only one of them.